The effect of l-carnitine supplementation on insulin resistance, sex hormone-binding globulin and lipid profile in overweight/obese women with polycystic ovary syndrome: a randomized clinical trial
- 2 November 2021
- journal article
- research article
- Published by Springer Nature in European Journal of Nutrition
- Vol. 61 (3) , 1199-1207
Abstract
Purpose Polycystic ovary syndrome (PCOS) is a common endocrine disorder among reproductive-age women. Insulin resistance and dyslipidemia are linked to PCOS. l-Carnitine supplementation as a management strategy for women with PCOS has been proposed. The effect of l-carnitine supplementation on insulin resistance, sex hormone-binding globulin (SHBG) and lipid profile in overweight/obese women with PCOS was investigated. Methods This randomized, double-blind, controlled clinical trial, was conducted on 62overweight/obese women with PCOS. Participants were randomly assigned into two groups to receive 1000 mg/day l-carnitine or placebo (1000 mg starch) for 12 weeks. Results l-Carnitine supplementation compared to the placebo showed a significant improvement in insulin [− 0.7 (− 7.3 to 4.0) vs. 0.7 (− 3.0 to 5.2); P = 0.001], homeostatic model assessment for insulin resistance [− 0.4 (− 1.7 to 1.1) vs. 0.0 (− 0.7 to 1.3); P = 0.002], quantitative insulin sensitivity check index (+ 0.01 ± 0.02 vs. − 0.01 ± 0.01; P = 0.02) and a non-significant change toward improvement in SHBG (+ 11.5 ± 40.2 vs. − 3.2 ± 40.2; P = 0.2). However, there was no significant differences between the two groups in serum levels of fasting plasma glucose, total cholesterol, triglyceride, low density lipoprotein-cholesterol and high density lipoprotein cholesterol (P > 0.05). Conclusion 12-week l-carnitine supplementation in overweight or obese women with PCOS ameliorate insulin resistance, but has no effect on SHBG and lipid profile. Studies with higher dosages and duration of l-carnitine intake are required. The trial was registered on 30 December 2019 at Iranian Registry of Clinical Trials IRCT20191016045131N1. Trial registration Registered on 30th December 2019 at Iranian Registry of Clinical Trials (IRCT20191016045131N1).Keywords
This publication has 42 references indexed in Scilit:
- Evolving utility of sex hormone-binding globulin measurements in clinical medicineCurrent Opinion in Endocrinology, Diabetes and Obesity, 2012
- Effects of Oral L-Carnitine Supplementation on Lipid Profile, Anemia, and Quality of Life in Chronic Renal Disease Patients under Hemodialysis: A Randomized, Double-Blinded, Placebo-Controlled TrialJournal of Nutrition and Metabolism, 2012
- Lipid levels in polycystic ovary syndrome: systematic review and meta-analysisFertility and Sterility, 2011
- Polycystic ovary syndrome: etiology, pathogenesis and diagnosisNature Reviews Endocrinology, 2011
- Ameliorating Hypertension and Insulin Resistance in Subjects at Increased Cardiovascular RiskHypertension, 2009
- l-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetesThe American Journal of Clinical Nutrition, 2009
- The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndromeClinical Endocrinology, 2008
- New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscleThe Journal of Physiology, 2007
- Therapeutic Effects of l‐Carnitine and Propionyl‐l‐carnitine on Cardiovascular Diseases: A ReviewAnnals of the New York Academy of Sciences, 2004
- Pharmacokinetics of L-CarnitineClinical Pharmacokinetics, 2003